Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Business Alignment PCL's annualized ROCE % for the quarter that ended in Jun. 2026 was 34.59%.
Business Alignment PCL (BKK:BIZ) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Business Alignment PCL (BKK:BIZ) has a ROCE % of 34.59% as of Jun. 2026.
Is Business Alignment PCL's ROCE % too high?
Business Alignment PCL's current ROCE % is 34.59%. The Medical Devices & Instruments industry median ROCE % is 2.97. Business Alignment PCL's value of 34.59% is 1064.6% above this industry median. Overall, Business Alignment PCL has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Business Alignment PCL's ROCE % compare to ABT and SYK?
Business Alignment PCL's ROCE % of 34.59% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.97. Business Alignment PCL's value of 34.59% is 1064.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.97, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Business Alignment PCL's current ROCE % of 34.59% is 1064.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Business Alignment PCL's current ROCE % is 34.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Business Alignment PCL stock overvalued right now?
Based on GuruFocus' analysis, Business Alignment PCL (BKK:BIZ) is currently considered Fairly Valued. The stock's GF Value™ is ฿5.42, compared to a current price of ฿5.95 — trading 9.8% above its estimated fair value. The current ROCE % is 34.59% and 1064.6% above the Medical Devices & Instruments industry median of 2.97. Business Alignment PCL's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Business Alignment PCL (BKK:BIZ), the current ROCE % is 34.59% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Business Alignment PCL (BKK:BIZ) Overvalued in 2026?
Based on GuruFocus' analysis, Business Alignment PCL stock appears to be overvalued.
The current stock price of ฿5.95 is trading 9.8% above its estimated GF Value™ of ฿5.42.
GuruFocus considers Business Alignment PCL to be Fairly Valued.
Key valuation signals for BKK:BIZ:
ROCE %: 34.59%
GF Value™: ฿5.42 vs. price of ฿5.95 (9.8% above fair value)
Industry Position: 1064.6% above the Medical Devices & Instruments median
No single metric tells the full story. See the BKK:BIZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Business Alignment PCL is engaged in the distribution and installation of medical equipment for cancer treatment through radiotherapy. The company operates through the sale of medical equipment segment which includes installation, repair, and maintenance. In addition, it also focuses on increasing the efficiency of medical equipment; and Hospital operations (specialized in cancer treatment). The company is a distributor for Radiotherapy products and Brachytheraphy products in Thailand and Cambodia. Geographically, it operates in the region of Thailand.
91GF Score
Get the complete analysis for BKK:BIZ
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BIZ has been successfully added to your 
